Do you want to volunteer for Clinical Trials? Register now

Find out more about Medical Trials

If you have any questions about our medical trials or other clinical studies in general please contact us.

The most common questions and answers are below.

FAQs

Q. Can I take part in a Clinical Trial?

A. There are rules about who can and can’t take part in a clinical trial these rules are often referred to as inclusion or exclusion criteria.

These Inclusion and exclusion criteria are designed to help ensure the safety of the people taking part and help make sure that the trial produces accurate results. These criteria could be based on your age, sex, any current or previous medical history and numerous other factors. As these selection criteria differ from study to study it is essential that your suitability for the trial is assessed before you are allowed to participate.

Back to top >

Q. If I am asked to take part in a study will I have to sign an informed consent form?

A. “Informed consent” is the process of describing / learning the facts about a clinical trial before deciding whether or not to participate. It is essential that you are able to make in “informed” decision about taking part in a study hence the name. If there are any changes made once a study has started you will be given additional information to ensure that you are kept informed.

To help you decide if you would like to take part, the doctor involved will explain the study to you. You will then be provided with an informed consent form that will include a lot of information about the trial; why it is taking place, how long it will take, the standard procedures, any risks or side effects you might experience and who will be involved.

The risks to you and potential benefits are explained in the informed consent form. You should take your time to consider this information carefully and then decide if you would like to sign it. Keep a copy of the informed consent form as it is helpful to refer to before, during and after the trial. If you aren’t given one immediately ask for a copy. You can also request more information, for example, a copy of the protocol (full study plan). No informed consent form may include any language that asks or appears to ask you to waive your legal rights, or that releases or appears to release the investigator, the sponsor, or the institution from liability for negligence.

PLEASE NOTE: IF AT ANY TIME YOU CHANGE YOUR MIND YOU CAN PULL OUT OF THE STUDY. BY SIGNING THE INFORMED CONSENT FORM THIS DOES NOT OBLIGATE YOU TO TAKE PART. IT MERELY CONFIRMS THAT YOU HAVE RECEIVED AND UNDERSTOOD THE STUDY INFORMATION THAT YOU HAVE BEEN GIVEN

Back to top >

Q. What should I do before signing the informed consent form?

A. Strongly consider what questions you would like to ask the doctors and nurses involved. You may also want to ask somebody else to come along to the meeting with you to support you or to ask any questions that you might forget It is not unheard of for people to take tape recorders or at the least a pen and paper into this meeting to record all the relevant answers to your questions. You may like to ask:

  1. When will the trial start?
  2. Is there anything I need to do to prepare (e.g stop drinking or smoking for a period before)?
  3. Why is the trial being conducted (what is its aim?)?
  4. Who will be running the trial and who will be looking after me before, during and afterwards?
  5. Has the compound / treatment been tested before? If so can they tell you more about this?
  6. What kinds of tests might you have to have?
  7. Will there be any lasting effects of this study after its finished?
  8. If I am a woman of childbearing potential, how long will I need to wait after the study has finished before becoming pregnant?
  9. How long will the trial take and will you need to stay overnight or in hospital?
  10. Will there be any side effects? (see below)
  11. Will I be compensated for my expenses or my time? If so how?
  12. Will I be told the outcome of the trial I take part in?
  13. Will there be any need for aftercare or follow up visits after the study has been completed? If so what will these involve?

Back to top >

Q. What will the side effects be?

A. It is very difficult to answer this question because it very much depends on the nature of the study and the treatments involved. You should discuss this thoroughly with your doctor and the people running the trial. However some of the more common side effects seen during Medical Trials include headaches, nausea, rashes / skin irritation, fatigue or other physical discomfort. Alternatively, there may be no side effects at all.

Back to top >

Q. Will I be safe?

A. There are very strict regulations and guidelines covering both ethical and legal aspects that apply to both medical practice and clinical trials. The trial that you are on should follow a carefully controlled protocol, and a study plan. Your safety is of primary importance to the conduct of the trial.

Every clinical trial has to be approved by an Ethics Committee (EC) in the EU to make sure the risks are as low as possible and are worth any potential benefits. An Ethics Committee is an independent committee of physicians, statisticians, lay persons, and other qualified experts. They make sure that before the study goes ahead (and even throughout the study) it is ethical and that the highest standards of safety are maintained.

Back to top >

Summary

It is important that before you consent to take part in a medical trial you appreciate that without your assistance new treatments may not be developed. However, you need to be completely comfortable with the situation and make sure that you know all of the risks that may be involved. Speak to the medical professionals involved and ask as many questions as you like. They are there to help.

View our Terms and Conditions.

Source: based on clinicaltrials.gov, cancer.gov and ich.org http://www.ifpma.org/ Last updated 8th April 8, 2006

Back to top >

News

CTI Clinical Trial and Consulting Services acquires Eurotrials

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Eurotrials, a full-service CRO, with more than 20 years of experience, and strong local expertise in Europe and Latin America. The acquisition strengthens CTI’s existing Real World Evidence business, adding significant presence and expertise in Europe […]

more >

Evotec, CRTD partner to discover novel therapies for retinal diseases

Evotec has entered into a research collaboration with the Center for Regenerative Therapies TU Dresden (CRTD) to discover novel small molecule candidates for retinal diseases. CRTD is a recognized leader in understanding the biology of stem cells to develop new therapies for neurodegenerative and hematological diseases. Under the terms of the collaboration, Evotec will leverage […]

more >

Egalet receives FDA tentative approval for expanded label for ARYMO ER

Egalet, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that the FDA has granted tentative approval for an expanded label for ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment […]

more >

Parkinson’s: Could this existing drug halt disease progression?

A 50-year-old drug that is commonly used to treat tapeworm infections is found to contain a molecule that can protect against Parkinson’s disease. Powered by WPeMatico

more >

Certara introduces New Investigator Awards program in Australia

Certara, a global leader in model-informed drug development and regulatory science, announced that Leigh Farrell, PhD, Vice President of Corporate Strategy and Business Development, is presenting the inaugural Certara New Investigator Awards in association with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT). The presentation will take place today at the Australasian […]

more >

CluePoints hires Borders and Estrella

CluePoints, a provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions for clinical trials, has announced two new strategic appointments to strengthen its business development team. Nick Borders and Rob Estrella join the CluePoints U.S. team to support its impressive global business growth, allowing the company to increase its expanding client base across North […]

more >